Available EU DMF/CEP
EU DMF
CEP
API Status
Commercial
Pipeline
Therapeutic Category
Alimentary tract & metabolism
Anti-infectives for systemic use
Antipyretic, analgesic and anti-inflammatory
Antineoplastic & immunomodulating agents
Blood & blood forming organs
Cardiovascular system
Genito-urinary system & sex hormones
Injectable forms
Musculo-skeletal system
Nervous system
Opthalmological preparations
Respiratory system
Available US DMF
US DMF
Available Japanese/Chinese DMF
Japanese DMF
Chinese DMF
Korean DMF

Repaglinide

CAS No.

135062-02-1

Innovator/marketer

Novonorm, Prandin

Polymorphic form

Form I

Therapeutic Area

Alimentary tract & metabolism

Status

Commercial

EU DMF readiness

US DMF readiness

021149

CEP

Drug description:

Repaglinide is an anti-diabetic agent belongs to the meglitinide class of short-acting insulin secretagogues.
Repaglinide is indicated for the treatment of non-insulin-dependent diabetes mellitus (type 2 diabetes).
It is formulated as tablets for oral route of administration.

Mechanism of action:

Repaglinide closes ATP-dependent potassium channels in the beta-cell membrane by binding at characterizable sites. It acts an ATP Binding Cassette Sub Family C Member 8 inhibitor. This potassium channel blockade depolarizes the beta-cell, which leads to an opening of calcium channels. The resulting increased calcium influx induces insulin secretion.

DISCLAIMER
Products protected by valid patents are not offered for commercial sale in countries where the sale of such products constitutes patent infringement but are offered solely for uses reasonably related to the development and submission of information under a law regulating the manufacture, use or sale of drugs. It is within the buyer’s responsibility and liability to check the patent situation of the product in the imported market(s).

OK